Medical device companies get scant love on Wall Street (Weekend Rounds)

Life science current events this week include medical device stocks snubbed from best bets, Neoprobe sells device business and Facebook changes pharma policy.

A review of life science events reported by MedCity News this week:

Medical device companies get scant Wall Street love. On Monday, Morgan Stanley health analysts picked five healthcare stocks that they believe investors should own now. Notably, only one is a medical device firm.

Neoprobe completes sale of device business; plans to change name. Neoprobe (NYSE Amex:NEOP) has completed the sale of its radiation detection business to Devicor Medical Products. The deal’s value could reach $50 million for Dublin, Ohio-based Neoprobe — $30 million up front and $20 million in royalties if Devicor’s sales of the acquired products exceed $21 million in any of the next five fiscal years, according to separate statements from the two companies.

Pharmas will monitor Facebook posts after site changes pharmas’ wall policy. Facebook will no longer allow pharmaceutical companies to block comments, a healthcare social media policy change that has led some companies to take down pages. But a number of companies, including Pfizer (NYSE:PFE) and AstraZeneca (NYSE:AZN), are maintaining their Facebook pages. From now on, however, they’ll keep a close eye to monitor what’s posted.

PPD in ‘exclusive talks’ with Carlyle Group about M&A deal, reports say. Bloomberg News reports that Carlyle is in exclusive talks to possibly acquire Wilmington, North Carolina-based PPD, which is the third-largest CRO in the industry with more than $1.4 billion in 2010 revenue.

Ohio fund tops list of biggest angel investment groups. The Ohio TechAngel Fund tops a list of the nation’s biggest angel investor groups by With 282 members, the Columbus, Ohio-based group was one of just three angel groups to boast more than 200 members. Los Angeles’s Tech Coast Angels, at 263, came in second on Entrepreneur’s list.